Abbott Laboratories $ABT Shares Sold by Investment House LLC

Investment House LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 55.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 10,394 shares of the healthcare product maker’s stock after selling 13,117 shares during the period. Investment House LLC’s holdings in Abbott Laboratories were worth $1,027,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Parkway Wealth Management Group LLC grew its stake in Abbott Laboratories by 3.2% during the 3rd quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker’s stock valued at $317,000 after acquiring an additional 98 shares in the last quarter. St. Johns Investment Management Company LLC increased its holdings in shares of Abbott Laboratories by 1.0% in the 2nd quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock valued at $895,000 after purchasing an additional 101 shares during the period. AA Financial Advisors LLC increased its holdings in shares of Abbott Laboratories by 1.7% in the 3rd quarter. AA Financial Advisors LLC now owns 6,186 shares of the healthcare product maker’s stock valued at $611,000 after purchasing an additional 101 shares during the period. Eagle Bay Advisors LLC lifted its position in shares of Abbott Laboratories by 1.2% in the third quarter. Eagle Bay Advisors LLC now owns 8,448 shares of the healthcare product maker’s stock worth $835,000 after purchasing an additional 102 shares in the last quarter. Finally, Richards Merrill & Peterson Inc. lifted its position in shares of Abbott Laboratories by 1.1% in the third quarter. Richards Merrill & Peterson Inc. now owns 9,562 shares of the healthcare product maker’s stock worth $945,000 after purchasing an additional 102 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on ABT shares. Weiss Ratings upgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday. TD Cowen cut their target price on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating for the company in a research report on Thursday. Piper Sandler reissued an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a research note on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.32.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Abbott Laboratories Stock Up 1.2%

ABT opened at $103.70 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $132.02. The business has a 50-day moving average of $105.15 and a 200-day moving average of $98.32. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a market capitalization of $179.45 billion, a PE ratio of 38.70, a price-to-earnings-growth ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42. The business had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.30 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.